Article | 2026 AAO Meeting
Remigromig Meets Primary Endpoint in BRUNELLO Trial
Both doses of the Wnt pathway agonist met the primary noninferiority endpoint in evaluation against ranibizumab in patients with DME, Donald J. D’Amico, MD, reported at AAO.







